First-in-class targeted microRNA therapy slows cancer tumor growth

A new cancer therapy developed by Purdue University researchers attacks tumors by tricking cancer cells into absorbing a snippet of RNA that naturally blocks cell division. As reported in Oncogene, tumors treated with the new therapy did not increase in size over the course of a 21-day study, while untreated tumors tripled in size over the same time period. The paper is tiled «A first-in-class fully modified version of miR-34a with outstanding stability, activity, and anti-tumor efficacy.»